GB9701684D0 - Novel compounds - Google Patents
Novel compoundsInfo
- Publication number
- GB9701684D0 GB9701684D0 GBGB9701684.4A GB9701684A GB9701684D0 GB 9701684 D0 GB9701684 D0 GB 9701684D0 GB 9701684 A GB9701684 A GB 9701684A GB 9701684 D0 GB9701684 D0 GB 9701684D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- novel compounds
- novel
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6478—Aspartic endopeptidases (3.4.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6413—Aspartic endopeptidases (3.4.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9701684.4A GB9701684D0 (en) | 1997-01-28 | 1997-01-28 | Novel compounds |
US09/009,191 US6319689B1 (en) | 1997-01-28 | 1998-01-20 | Asp2 |
CA002221686A CA2221686A1 (en) | 1997-01-28 | 1998-01-27 | Asp2 |
EP98300573A EP0855444B1 (en) | 1997-01-28 | 1998-01-27 | Aspartic proteinase 2 (ASP2) |
EP06120869A EP1811035A1 (en) | 1997-01-28 | 1998-01-27 | Aspartic proteinase 2 (ASP2) |
DE69835913T DE69835913T2 (en) | 1997-01-28 | 1998-01-27 | Aspartate proteinase 2 (ASP2) |
JP10016134A JPH10327875A (en) | 1997-01-28 | 1998-01-28 | Aspartic acid protease asp2 |
JP11219665A JP2000060579A (en) | 1997-01-28 | 1999-08-03 | Aspartic proteinase asp2 |
US09/969,671 US6870030B2 (en) | 1997-01-28 | 2001-10-03 | Asp2 |
US10/308,365 US20030109022A1 (en) | 1997-01-28 | 2002-12-03 | Asp2 |
US10/829,717 US20050101556A1 (en) | 1997-01-28 | 2004-04-22 | Asp2 |
US11/476,286 US20060263852A1 (en) | 1997-01-28 | 2006-06-28 | Asp2 |
US11/476,984 US20060269539A1 (en) | 1997-01-28 | 2006-06-28 | Asp2 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9701684.4A GB9701684D0 (en) | 1997-01-28 | 1997-01-28 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
GB9701684D0 true GB9701684D0 (en) | 1997-03-19 |
Family
ID=10806677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB9701684.4A Pending GB9701684D0 (en) | 1997-01-28 | 1997-01-28 | Novel compounds |
Country Status (6)
Country | Link |
---|---|
US (6) | US6319689B1 (en) |
EP (2) | EP1811035A1 (en) |
JP (2) | JPH10327875A (en) |
CA (1) | CA2221686A1 (en) |
DE (1) | DE69835913T2 (en) |
GB (1) | GB9701684D0 (en) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9701684D0 (en) * | 1997-01-28 | 1997-03-19 | Smithkline Beecham Plc | Novel compounds |
EP1939297A1 (en) | 1998-09-24 | 2008-07-02 | Pharmacia & Upjohn Company LLC | Alzheimer's disease secretase |
US6699671B1 (en) * | 1998-09-24 | 2004-03-02 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
US6844148B1 (en) * | 1998-09-24 | 2005-01-18 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
US20040234976A1 (en) * | 1998-09-24 | 2004-11-25 | Gurney Mark E. | Alzheimer's disease secretase, app substrates therefor, and uses therefor |
JP2002526081A (en) * | 1998-09-24 | 2002-08-20 | ファルマシア・アンド・アップジョン・カンパニー | Alzheimer's disease secretase |
US7115410B1 (en) * | 1999-02-10 | 2006-10-03 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
US7456007B1 (en) * | 1998-12-31 | 2008-11-25 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
EP1445263A1 (en) * | 1999-02-10 | 2004-08-11 | Elan Pharmaceuticals, Inc. | Human beta-secretase enzyme, inhibitors and their compositions and uses |
GB2389114B (en) * | 1999-02-10 | 2004-02-04 | Elan Pharm Inc | Mouse b-secretase enzyme |
CN1390232A (en) * | 1999-02-10 | 2003-01-08 | 艾兰制药公司 | Human beta-secretase enzyme, inhibitor, and its composition and use |
WO2000058479A1 (en) * | 1999-03-26 | 2000-10-05 | Amgen Inc. | Beta secretase genes and polypeptides |
US20020049303A1 (en) * | 1999-06-28 | 2002-04-25 | Tang Jordan J. N. | Catalytically active recombinant memapsin and methods of use thereof |
EP1496124A1 (en) * | 1999-06-28 | 2005-01-12 | Oklahoma Medical Research Foundation | Catalytically active recombinant memapsin and methods of use thereof |
AU2004202058B2 (en) * | 1999-06-28 | 2007-08-23 | Oklahoma Medical Research Foundation | Inhibitors of memapsin 2 and use thereof |
AU5771500A (en) * | 1999-06-28 | 2001-01-31 | Oklahoma Medical Research Foundation | Catalytically active recombinant memapsin and methods of use thereof |
US20090162883A1 (en) * | 1999-09-23 | 2009-06-25 | Pharmacia & Upjohn Company | Alzheimer's Disease Secretase, APP Substrates Thereof, and Uses Thereof |
GB9924957D0 (en) * | 1999-10-21 | 1999-12-22 | Smithkline Beecham Plc | Novel treatment |
US7514408B1 (en) | 1999-12-02 | 2009-04-07 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
IL153943A0 (en) | 2000-07-19 | 2003-07-31 | Upjohn Co | SUBSTRATES AND ASSAYS FOR beta-SECRETASE ACTIVITY |
DE60126970T2 (en) * | 2000-09-22 | 2007-11-22 | Wyeth | CRYSTAL STRUCTURE OF BACE AND USES THEREOF |
US20040121947A1 (en) * | 2000-12-28 | 2004-06-24 | Oklahoma Medical Research Foundation | Compounds which inhibit beta-secretase activity and methods of use thereof |
EP1390497A2 (en) | 2001-05-25 | 2004-02-25 | Genset | Human cdnas and proteins and uses thereof |
US7186539B1 (en) | 2001-08-31 | 2007-03-06 | Pharmacia & Upjohn Company | Method for refolding enzymes |
US20060234944A1 (en) * | 2001-10-23 | 2006-10-19 | Oklahoma Medical Reseach Foundation | Beta-secretase inhibitors and methods of use |
AU2002359301B2 (en) * | 2001-10-23 | 2008-07-03 | Comentis, Inc. | Beta-secretase inhibitors and methods of use |
JP4272070B2 (en) * | 2002-02-21 | 2009-06-03 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | Modified BACE |
US20030224512A1 (en) * | 2002-05-31 | 2003-12-04 | Isis Pharmaceuticals Inc. | Antisense modulation of beta-site APP-cleaving enzyme expression |
US7829694B2 (en) * | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US7605249B2 (en) | 2002-11-26 | 2009-10-20 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US7618948B2 (en) * | 2002-11-26 | 2009-11-17 | Medtronic, Inc. | Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA |
US20050074456A1 (en) * | 2002-12-04 | 2005-04-07 | Marcus Ballinger | Constructs for homogenously processed preparations of beta site APP-cleaving enzyme |
US7994149B2 (en) | 2003-02-03 | 2011-08-09 | Medtronic, Inc. | Method for treatment of Huntington's disease through intracranial delivery of sirna |
US7732591B2 (en) * | 2003-11-25 | 2010-06-08 | Medtronic, Inc. | Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna |
WO2004099402A1 (en) * | 2003-05-02 | 2004-11-18 | Elan Pharmaceuticals, Inc. | Glycosylation variants of bace |
US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
US20060019368A1 (en) * | 2004-07-20 | 2006-01-26 | Marcus Ballinger | Constructs for homogenously processed preparations of beta site APP-cleaving enzyme |
US20060253068A1 (en) * | 2005-04-20 | 2006-11-09 | Van Bilsen Paul | Use of biocompatible in-situ matrices for delivery of therapeutic cells to the heart |
EP1885854B1 (en) * | 2005-05-06 | 2012-10-17 | Medtronic, Inc. | Methods and sequences to suppress primate huntington gene expression |
US7902352B2 (en) * | 2005-05-06 | 2011-03-08 | Medtronic, Inc. | Isolated nucleic acid duplex for reducing huntington gene expression |
US20080280843A1 (en) * | 2006-05-24 | 2008-11-13 | Van Bilsen Paul | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
US20070161590A1 (en) * | 2005-06-28 | 2007-07-12 | Medtronic, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
US9133517B2 (en) | 2005-06-28 | 2015-09-15 | Medtronics, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
EP1922083A2 (en) * | 2005-08-10 | 2008-05-21 | Oklahoma Medical Research Foundation | Truncated memapsin 2 for use for treating alzheimer's disease |
WO2007081534A2 (en) * | 2005-12-22 | 2007-07-19 | Pfizer Products Inc | Method of producing catalytically active bace2 enzymes |
US9273356B2 (en) | 2006-05-24 | 2016-03-01 | Medtronic, Inc. | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
TW200815349A (en) * | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
US20080039415A1 (en) * | 2006-08-11 | 2008-02-14 | Gregory Robert Stewart | Retrograde transport of sirna and therapeutic uses to treat neurologic disorders |
US9375440B2 (en) * | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US8324367B2 (en) | 2006-11-03 | 2012-12-04 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US7988668B2 (en) * | 2006-11-21 | 2011-08-02 | Medtronic, Inc. | Microsyringe for pre-packaged delivery of pharmaceuticals |
US7819842B2 (en) * | 2006-11-21 | 2010-10-26 | Medtronic, Inc. | Chronically implantable guide tube for repeated intermittent delivery of materials or fluids to targeted tissue sites |
US20080171906A1 (en) * | 2007-01-16 | 2008-07-17 | Everaerts Frank J L | Tissue performance via hydrolysis and cross-linking |
TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
EP2281824A1 (en) | 2009-08-07 | 2011-02-09 | Noscira, S.A. | Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
SG190682A1 (en) | 2010-11-10 | 2013-07-31 | Genentech Inc | Methods and compositions for neural disease immunotherapy |
WO2012069428A1 (en) | 2010-11-22 | 2012-05-31 | Noscira, S.A. | Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions |
WO2016081639A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Antibodies against bace1 and use thereof for neural disease immunotherapy |
JP6993228B2 (en) | 2014-11-19 | 2022-03-03 | ジェネンテック, インコーポレイテッド | Anti-transferrin receptor / anti-BACE1 multispecific antibody and usage |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0732399A3 (en) | 1990-03-05 | 1997-03-12 | Cephalon Inc | Chymotrypsin-like proteases and their inhibitors |
US5586226A (en) | 1990-05-16 | 1996-12-17 | Canon Kabushiki Kaisha | Control method and device for a unicolor printer |
US5252463A (en) | 1990-06-22 | 1993-10-12 | The Du Pont Merck Pharmaceutical Company | Clipsin, a chymotrypsin-like protease and method of using same |
HUT69771A (en) | 1990-08-17 | 1995-09-28 | Univ Boston | Proteases causing abnormal degradation of amyloid beta-proteine precursors |
US5292652A (en) * | 1990-10-05 | 1994-03-08 | Athena Neurosciences, Inc. | Amyloidin protease and uses thereof |
US5441870A (en) | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
WO1995013084A1 (en) | 1992-05-11 | 1995-05-18 | Miles Inc. | Cathepsin d is an amyloidogenic protease in alzheimer's disease |
US6610493B1 (en) | 1993-06-17 | 2003-08-26 | Brigham And Women's Hospital | Screening compounds for the ability to alter the production of amyloid-β peptide |
IL107250A (en) * | 1993-10-12 | 2001-08-08 | Yeda Res & Dev | Dna molecules involved in programmed cell death, proteins encoded thereby and methods and compositions using said dna molecules and proteins |
US6221645B1 (en) * | 1995-06-07 | 2001-04-24 | Elan Pharmaceuticals, Inc. | β-secretase antibody |
US6329163B1 (en) * | 1995-06-07 | 2001-12-11 | Elan Pharmaceuticals, Inc. | Assays for detecting β-secretase inhibition |
EP0871720A2 (en) * | 1995-06-07 | 1998-10-21 | Athena Neurosciences, Inc. | Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition |
US5744346A (en) * | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
AU4589297A (en) | 1996-10-07 | 1998-05-05 | Scios Inc. | Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase |
AU1684097A (en) * | 1996-12-11 | 1998-07-03 | Athena Neurosciences, Inc. | Beta-secretase isolated from human 293 cells |
EP0848062A3 (en) * | 1996-12-14 | 2000-07-05 | Smithkline Beecham Corporation | Aspartic protease ASP1 |
GB9626022D0 (en) * | 1996-12-14 | 1997-01-29 | Smithkline Beecham Plc | Novel compounds |
GB9701684D0 (en) * | 1997-01-28 | 1997-03-19 | Smithkline Beecham Plc | Novel compounds |
AU758004B2 (en) | 1997-12-17 | 2003-03-13 | Genset S.A. | Extended cDNAs for secreted proteins |
WO1999033963A1 (en) | 1997-12-31 | 1999-07-08 | Chiron Corporation | Metastatic cancer regulated gene |
JP3868740B2 (en) | 1998-03-10 | 2007-01-17 | ジェネンテック・インコーポレーテッド | Novel polypeptide and nucleic acid encoding the same |
JP2002526081A (en) | 1998-09-24 | 2002-08-20 | ファルマシア・アンド・アップジョン・カンパニー | Alzheimer's disease secretase |
US6699671B1 (en) * | 1998-09-24 | 2004-03-02 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
US6313268B1 (en) * | 1998-10-16 | 2001-11-06 | Vivian Y. H. Hook | Secretases related to Alzheimer's dementia |
CN1390232A (en) * | 1999-02-10 | 2003-01-08 | 艾兰制药公司 | Human beta-secretase enzyme, inhibitor, and its composition and use |
KR20030002292A (en) | 1999-03-08 | 2003-01-08 | 제넨테크, 인크. | Secreted and Transmembrane Polypeptides and Nucleic Acids Encoding the Same |
WO2000058479A1 (en) | 1999-03-26 | 2000-10-05 | Amgen Inc. | Beta secretase genes and polypeptides |
AU5771500A (en) | 1999-06-28 | 2001-01-31 | Oklahoma Medical Research Foundation | Catalytically active recombinant memapsin and methods of use thereof |
EP1067182A3 (en) | 1999-07-08 | 2001-11-21 | Helix Research Institute | Secretory protein or membrane protein |
GB9924957D0 (en) | 1999-10-21 | 1999-12-22 | Smithkline Beecham Plc | Novel treatment |
US20030211106A1 (en) | 2000-08-21 | 2003-11-13 | Tornetta Mark A | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
-
1997
- 1997-01-28 GB GBGB9701684.4A patent/GB9701684D0/en active Pending
-
1998
- 1998-01-20 US US09/009,191 patent/US6319689B1/en not_active Expired - Fee Related
- 1998-01-27 EP EP06120869A patent/EP1811035A1/en not_active Withdrawn
- 1998-01-27 DE DE69835913T patent/DE69835913T2/en not_active Expired - Fee Related
- 1998-01-27 CA CA002221686A patent/CA2221686A1/en not_active Abandoned
- 1998-01-27 EP EP98300573A patent/EP0855444B1/en not_active Expired - Lifetime
- 1998-01-28 JP JP10016134A patent/JPH10327875A/en active Pending
-
1999
- 1999-08-03 JP JP11219665A patent/JP2000060579A/en active Pending
-
2001
- 2001-10-03 US US09/969,671 patent/US6870030B2/en not_active Expired - Fee Related
-
2002
- 2002-12-03 US US10/308,365 patent/US20030109022A1/en not_active Abandoned
-
2004
- 2004-04-22 US US10/829,717 patent/US20050101556A1/en not_active Abandoned
-
2006
- 2006-06-28 US US11/476,286 patent/US20060263852A1/en not_active Abandoned
- 2006-06-28 US US11/476,984 patent/US20060269539A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE69835913D1 (en) | 2006-11-02 |
US6319689B1 (en) | 2001-11-20 |
CA2221686A1 (en) | 1998-07-28 |
EP0855444A3 (en) | 2001-02-28 |
JPH10327875A (en) | 1998-12-15 |
EP0855444A2 (en) | 1998-07-29 |
EP1811035A1 (en) | 2007-07-25 |
US6870030B2 (en) | 2005-03-22 |
DE69835913T2 (en) | 2007-09-13 |
JP2000060579A (en) | 2000-02-29 |
US20060263852A1 (en) | 2006-11-23 |
US20060269539A1 (en) | 2006-11-30 |
EP0855444B1 (en) | 2006-09-20 |
US20030109022A1 (en) | 2003-06-12 |
US20050101556A1 (en) | 2005-05-12 |
US20030036112A1 (en) | 2003-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EG24412A (en) | Novel compounds | |
EG24177A (en) | Novel compounds | |
GB9701684D0 (en) | Novel compounds | |
GB9706255D0 (en) | Novel compounds | |
GB9707830D0 (en) | Novel compounds | |
GB9703492D0 (en) | Novel compounds | |
GB9704461D0 (en) | Novel compounds | |
GB9705619D0 (en) | Novel compounds | |
GB9700281D0 (en) | Novel compounds | |
GB9700590D0 (en) | Novel compounds | |
GB9700687D0 (en) | Novel compounds | |
GB9700688D0 (en) | Novel compounds | |
GB9700689D0 (en) | Novel compounds | |
GB9707831D0 (en) | Novel compounds | |
GB9700694D0 (en) | Novel compounds | |
GB9700901D0 (en) | Novel compounds | |
GB9700902D0 (en) | Novel compounds | |
GB9701597D0 (en) | Novel compounds | |
GB9703011D0 (en) | Novel compounds | |
GB9703333D0 (en) | Novel compounds | |
GB9703334D0 (en) | Novel compounds | |
GB9712586D0 (en) | Novel compounds | |
GB9703491D0 (en) | Novel compounds | |
GB9703493D0 (en) | Novel compounds | |
GB9703402D0 (en) | Novel compounds |